筛查后(间期)结直肠癌的死亡率与未筛查患者中结直肠癌的死亡率相当——一项随机乙状结肠镜筛查试验
该研究为挪威随机乙状结肠镜筛查试验的二次分析,纳入98,684名50-64岁参与者,比较筛查后30天及以上诊断的间期癌组(n=163)与未筛查组临床诊断结直肠癌患者(n=1740)的死亡率。中位随访14.8年,间期癌组结直肠癌死亡43例,对照组525例;结直肠癌死亡率(校正HR 0.98;95%CI 0.72-1.35;P=0.92)、直肠乙状结肠癌死亡率(校正HR 1.10;95%CI 0.63-1.92;P=0.74)及全因死亡率(校正HR 0.99;95%CI 0.76-1.27;P=0.91)在两组间均无显著差异。
要点
- 间期结直肠癌与未筛查临床诊断结直肠癌的结直肠癌死亡率无显著差异(校正HR 0.98;95%CI 0.72-1.35)。
- 直肠乙状结肠癌死亡率两组无显著差异(校正HR 1.10;95%CI 0.63-1.92)。
- 全因死亡率两组无显著差异(校正HR 0.99;95%CI 0.76-1.27)。
核心结论
- 在该随机乙状结肠镜筛查试验中,间期结直肠癌患者与未筛查的临床诊断结直肠癌患者死亡率无显著差异。
研究设计与样本
- 挪威随机乙状结肠镜筛查试验的二次分析,1999年至2001年随机分配98,684名50-64岁参与者接受(n=20,552)或不接受(n=78,126)乙状结肠镜筛查邀请,中位随访14.8年。
- 比较筛查后30天及以上诊断结直肠癌的间期癌组(n=163)与未筛查组临床诊断结直肠癌患者(n=1740),采用Cox回归校正年龄和性别,按肿瘤部位分层分析。
主要发现
- 随访期间间期癌组结直肠癌死亡43例,对照组525例。
- 结直肠癌死亡率校正HR 0.98(95%CI 0.72-1.35;P=0.92),两组无显著差异。
- 直肠乙状结肠癌死亡率校正HR 1.10(95%CI 0.63-1.92;P=0.74),两组无显著差异。
- 全因死亡率校正HR 0.99(95%CI 0.76-1.27;P=0.91),两组无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Endoscopic screening for colorectal cancer (CRC) is performed at longer time intervals than the fecal occult blood test or screenings for breast or prostate cancer. This causes concerns about interval cancers, which have been proposed to progress more rapidly. We compared outcomes of patients with interval CRCs after sigmoidoscopy screening vs outcomes of patients with CRC who had not been screened. METHODS: We performed a secondary analysis of a randomized sigmoidoscopy screening trial in Norway with 98,684 participants (age range, 50-64 years) who were randomly assigned to groups that were (n = 20,552) or were not (n = 78,126) invited for sigmoidoscopy screening from 1999 through 2001; participants were followed up for a median 14.8 years. We compared CRC mortality and all-cause mortality between individuals who underwent screening and were diagnosed with CRC 30 days or longer after screening (interval cancer group, n = 163) and individuals diagnosed with CRC in the nonscreened group (controls, n = 1740). All CRCs in the control group were identified when they developed symptoms (clinically detected CRCs). Analyses were stratified by cancer site. We used Cox regression to estimate hazard ratio (HRs), adjusted for age and sex. RESULTS: Over the follow-up period, 43 individuals in the interval cancer group died from CRC; among controls, 525 died from CRC. CRC mortality (adjusted HR, 0.98; 95% confidence interval, 0.72-1.35; P = .92), rectosigmoid cancer mortality (adjusted HR, 1.10; 95% confidence interval, 0.63-1.92; P = .74), and all-cause mortality (adjusted HR, 0.99; 95% confidence interval, 0.76-1.27; P = .91) did not differ significantly between the interval cancer group and controls. CONCLUSIONS: In this randomized sigmoidoscopy screening trial, mortality did not differ significantly between individuals with interval CRCs and unscreened patients with clinically detected CRCs. ClinicalTrials.gov identifier: NCT00119912.
引用
- Jodal HC, Løberg M, Holme Ø, et al. Mortality From Postscreening (Interval) Colorectal Cancers Is Comparable to That From Cancer in Unscreened Patients-A Randomized Sigmoidoscopy Trial. Gastroenterology. 2018. PMID: 30165051. doi:10.1053/j.gastro.2018.08.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。